Galera Therapeutics, INC

Galera Therapeutics, Inc. has completed its merger with Obsidian Therapeutics, Inc., becoming a wholly owned subsidiary and ceasing its OTCQB listing.

Galera Therapeutics, Inc. announced a one-for-two hundred reverse stock split effective July 12, 2026, to adjust its common stock.

Galera Therapeutics, Inc. has announced a one-for-two hundred reverse stock split of its common stock, effective July 12, 2026.

Galera Therapeutics announced the mandatory conversion of all outstanding Series B Preferred Stock into common stock, eliminating preferred shares and settling fractional interests with cash.

Galera Therapeutics, Inc. has amended its Certificate of Incorporation to increase authorized shares and grant stockholders the right to act by written consent, alongside adopting new Amended and Restated Bylaws.

Galera Therapeutics stockholders approved director elections, ratified auditor appointment, and authorized significant amendments to the company's charter, including a potential reverse stock split.

Galera Therapeutics reports Q1 2026 results, detailing a significant merger with Obsidian Therapeutics, a concurrent $350M PIPE financing, and substantial doubt about its ability to continue as a going concern.

Galera Therapeutics has completed a strategic pivot, selling its dismutase mimetics assets and focusing on a new breast cancer therapy, while securing additional funding.

Galera Therapeutics, Inc. has shifted its strategic focus to advanced breast cancer therapies following an acquisition, but faces substantial doubt about its ability to continue as a going concern.

Galera Therapeutics reports Q1 2025 results, highlighting a strategic shift towards breast cancer treatment following the acquisition of Nova Pharmaceuticals and ongoing efforts to secure additional funding.

Galera Therapeutics reported its Q3 2024 results, highlighting significant reductions in operating expenses and a net loss, while also facing an uncertain future after stockholders rejected the proposed plan of dissolution.

Galera Therapeutics plans to dissolve and liquidate the company after failing to find a viable strategic alternative, pending stockholder approval.

Galera Therapeutics reports a significant net income of $149 million for 2025, driven by asset sales and a strategic pivot to advanced breast cancer therapies after divesting its dismutase mimetics portfolio.

Galera Therapeutics pivots to breast cancer drug development following the acquisition of Nova Pharmaceuticals, focusing on aggressive subtypes like metaplastic breast cancer.

Galera Therapeutics halts clinical trials and explores strategic alternatives following an FDA rejection and disappointing trial results.

Galera Therapeutics and Obsidian Therapeutics announce a merger, with Obsidian's OBX-115 TIL therapy showing promising efficacy in advanced melanoma.

Galera Therapeutics and Obsidian Therapeutics have entered into an Agreement and Plan of Merger, with Galera merging into a subsidiary of a newly formed parent company.

Emerald Bioventures, LLC converted 20,813.8186 shares of Series B Preferred Stock into 20,813,818 shares of Galera Therapeutics common stock.

Obsidian Therapeutics announced positive Phase 2 clinical results for its lead TIL cell therapy candidate, OBX-115, in patients with advanced melanoma.

Obsidian Therapeutics announced an oral presentation of Phase 2 clinical data for its OBX-115 therapy in advanced melanoma at the 2026 ASCO Annual Meeting.

Galera Therapeutics and Obsidian Therapeutics have entered into a merger agreement to combine their businesses, creating a new entity with a focus on advancing their respective pipelines.

Galera Therapeutics, Inc. has entered into a definitive merger agreement with Obsidian Therapeutics, Inc. in an all-stock transaction expected to close by the third quarter of 2026.

Galera Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on February 24, 2025, to elect directors and ratify the appointment of its independent auditor.

Galera Therapeutics is seeking stockholder approval for a plan to liquidate and dissolve the company, following a strategic review and the cessation of clinical development.

Parvinder Singh Hyare reports beneficial ownership of 13,521,921 shares of Galera Therapeutics following a mandatory conversion of Series B Preferred Stock.

Emerald Bioventures, LLC and Timothy Opler have increased their beneficial ownership in Galera Therapeutics to 30.2% following a mandatory conversion of Series B Preferred Stock.

Emerald Bioventures, LLC and Timothy Opler have filed a Schedule 13D, disclosing beneficial ownership of approximately 26.5% of Galera Therapeutics, Inc. common stock, following a merger and private placement.

Nancy T. Chang, a director of Galera Therapeutics, Inc., has updated her beneficial ownership following a merger and private placement, now holding 5.9% of the company's common stock.

Investment firm Ikarian Capital, LLC and Neil Shahrestani have jointly disclosed a 9.99% beneficial ownership stake in Galera Therapeutics, Inc., holding 7,538,690 shares of common stock as of December 31, 2024.